JPMorgan Starts RayzeBio (RYZB) at Overweight; pure-play in radiopharmaceuticals
Tweet Send to a Friend
(Updated - October 10, 2023 7:51 AM EDT)
JPMorgan analyst Jessica Fye initiates coverage on RayzeBio (NASDAQ: RYZB) with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Jessica Fye initiates coverage on RayzeBio (NASDAQ: RYZB) with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
